Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells

Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells , Prospective, Open, Multicenter Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02090803

Acronym

VIRAUTO6

Enrollment

189

Registered

2014-03-18

Start date

2012-08-31

Completion date

2015-03-31

Last updated

2017-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Diseases

Brief summary

The purpose of this study is to assess the human herpes virus reactivation 6 post autologous stem cells in 196 patients. The aim of our study was to describe the incidence of reactivation of HHV-6 in patients requiring autologous HSCT and determine the pathogenic role in this target population.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* all patients hospitalized in the Hematology Clinic of Saint-Etienne and Clermont-Ferrand and receiving autologous hematopoietic stem cells, according to the decision of the Consultative Meeting Multidisciplinary service; * Autologous recipients are included irrespective of causal hemopathy (myeloma, lymphoma, acute leukemia, mainly).

Exclusion criteria

* The non-consenting patients or unable to give consent

Design outcomes

Primary

Measure	Time frame	Description
HHV-6 biological reactivation	40 days	HHV-6 biological reactivation (blood viral load) is defined by a detectable viral load HHV-6 and\> 450 copies / mL on two occasions one week apart.

Secondary

Measure	Time frame
Aplasia output or engraftment	40 days
Reconstitution of hematopoiesis	40 days
Disease HHV-6	40 days

Countries

France

Outcome results